Molecular and Epigenetic Biomarkers in Luminal Androgen Receptor: A Triple Negative Breast Cancer Subtype

2016 ◽  
Vol 20 (10) ◽  
pp. 610-613 ◽  
Author(s):  
Gaëlle Judes ◽  
Aslihan Dagdemir ◽  
Seher Karsli-Ceppioglu ◽  
André Lebert ◽  
Marie-Mélanie Dauplat ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Subtype ◽  
Epigenetic Biomarkers ◽  
Cancer Subtype

scholarly journals Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triple-negative breast cancer subtype by transcriptome profiling

Oncotarget ◽  
2018 ◽  
Vol 9 (70) ◽  
pp. 33348-33359 ◽  
Author(s):  
Khalid N. Al-Zahrani ◽  
David P. Cook ◽  
Barbara C. Vanderhyden ◽  
Luc A. Sabourin
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Subtype ◽  
Transcriptome Profiling ◽  
Cancer Subtype

Androgen Receptor-Positive Triple Negative Breast Cancer: A Unique Breast Cancer Subtype

2013 ◽  
Vol 21 (2) ◽  
pp. 361-367 ◽  
Author(s):  
Lee J. McGhan ◽  
Ann E. McCullough ◽  
Cheryl A. Protheroe ◽  
Amylou C. Dueck ◽  
James J. Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Subtype ◽  
Cancer Subtype

scholarly journals Expression of long non‐coding RNA ENSG 00000226738 (Lnc KLHDC 7B) is enriched in the immunomodulatory triple‐negative breast cancer subtype and its alteration promotes cell migration, invasion, and resistance to cell death

2019 ◽  
Vol 13 (4) ◽  
pp. 909-927 ◽  
Author(s):  
Fredy Omar Beltrán‐Anaya ◽  
Sandra Romero‐Córdoba ◽  
Rosa Rebollar‐Vega ◽  
Oscar Arrieta ◽  
Verónica Bautista‐Piña ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Death ◽  
Cell Migration ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Subtype ◽  
Non Coding Rna ◽  
Cancer Subtype ◽  
Long Non Coding Rna

PKIB expression strongly correlated with phosphorylated Akt expression in breast cancers and also with triple-negative breast cancer subtype

2012 ◽  
Vol 45 (4) ◽  
pp. 229-233 ◽  
Author(s):  
Ken Dabanaka ◽  
Suyoun Chung ◽  
Hidewaki Nakagawa ◽  
Yusuke Nakamura ◽  
Takehiro Okabayashi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Subtype ◽  
Strongly Correlated ◽  
Breast Cancers ◽  
Phosphorylated Akt ◽  
Cancer Subtype

Tumor-infiltrating lymphocytes in androgen receptor-positive, triple-negative breast cancer.

2018 ◽  
Vol 36 (5_suppl) ◽  
pp. 5-5 ◽  
Author(s):  
Roberto Antonio Leon-Ferre ◽  
Mei-Yin Polley ◽  
Heshan Liu ◽  
Victoria Cafourek ◽  
Judy Caroline Boughey ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Androgen Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Subtype ◽  
Metastatic Breast ◽  
Tumor Infiltrating Lymphocytes ◽  
Surgical Specimen ◽  
Er Positive ◽  
Infiltrating Lymphocytes

5 Background: Triple-negative breast cancer (TNBC) is an immunogenic breast cancer subtype, with a greater percentage of tumors containing tumor-infiltrating lymphocytes (TILs) compared to non-TNBC. TILs are prognostic for recurrence and predictive for chemotherapy benefit in TNBC, but not in estrogen receptor (ER)-positive tumors. A subset of TNBC expresses the androgen receptor (AR), and resembles ER-positive breast cancer in terms of demographics (older age) and clinical course (later recurrences that tend to involve bone). However, little is known regarding the association between TILs and AR expression in TNBC. Methods: From a cohort of 9982 women with surgically-treated non-metastatic breast cancer, patients who met criteria for TNBC (ER/PR < 1% and HER2-negative) by centralized-pathology review were included as previously published [Leon-Ferre et al, Breast Cancer Res Treat 2017]. Stromal TILs in these tumors were quantified on full-face hematoxylin and eosin sections from the surgical specimen, following the 2014 TIL Working Group recommendations [Salgado et al, Ann Oncol 2014]. The expression of AR [EPR1535(2), Abcam] was scored as a continuous variable (1% increments), and categorized as absent (0%), low (1-25% ), low-moderate (26-50%) moderate (51-75%) and high (> 75%) and correlated with TIL density. Results: 605 patients met criteria for TNBC. The median age was 56 years. Most tumors were T1-2 (95%), N0-1 (86%), and high grade (88%). The median stromal TIL content was 20% (0-90%). Tumor tissue was available for AR staining in 509/605 patients. 165 (32%) tumors expressed AR as follows: low: 12%, low-moderate: 7%, moderate: 5%, and high: 8%. Apocrine tumors (n = 30) expressed AR most frequently (86%) and at higher levels (AR high: 50%). For all 509 tumors, the median stromal TIL content according to AR expression was AR absent: 20%, AR low: 20%, AR low-moderate: 15%, AR high: 10%. AR and stromal TILs (both as continuous variables) demonstrated a weak inverse correlation (correlation coefficient -0.1064, p = 0.017). Conclusions: AR expression in TNBC is associated with lower levels of stromal TILs. Additional data correlating the AR, stromal TILs and outcomes in this cohort will be presented at the meeting.

scholarly journals S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype

2015 ◽  
Vol 137 (9) ◽  
pp. 2093-2103 ◽  
Author(s):  
Sidse Ehmsen ◽  
Lea Tykgaard Hansen ◽  
Martin Bak ◽  
Charlotte Brasch-Andersen ◽  
Henrik J Ditzel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Prognostic Biomarker ◽  
Breast Cancer Subtype ◽  
Cancer Subtype

Targeted Drug Therapy to Overcome Chemoresistance in Triple-negative Breast Cancer

2020 ◽  
Vol 20 (8) ◽  
pp. 559-572
Author(s):  
Mamta Kumari ◽  
Praveen Thaggikuppe Krishnamurthy ◽  
Piyong Sola
Keyword(s):  
Breast Cancer ◽  
Drug Delivery ◽  
Side Effects ◽  
Triple Negative Breast Cancer ◽  
Anticancer Agents ◽  
Triple Negative ◽  
Breast Cancer Subtype ◽  
Cancer Subtype ◽  
Prevent Tumor Growth ◽  
Target Side

Triple-negative Breast Cancer (TNBC) is the most aggressive and prevailing breast cancer subtype. The chemotherapeutics used in the treatment of TNBC suffer from chemoresistance, dose-limiting toxicities and off-target side effects. As a result, conventional chemotherapeutics are unable to prevent tumor growth, metastasis and result in failure of therapy. Various new targets such as BCSCs surface markers (CD44, CD133, ALDH1), signaling pathways (IL-6/JAK/STAT3, notch), pro and anti-apoptotic proteins (Bcl-2, Bcl-xL, DR4, DR5), hypoxic factors (HIF-1α, HIF-2α) and drug efflux transporters (ABCC1, ABCG2 and ABCB1) have been exploited to treat TNBC. Further, to improve the efficacy and safety of conventional chemotherapeutics, researchers have tried to deliver anticancer agents specifically to the TNBCs using nanocarrier based drug delivery. In this review, an effort has been made to highlight the various factors responsible for the chemoresistance in TNBC, novel molecular targets of TNBC and nano-delivery systems employed to achieve sitespecific drug delivery to improve efficacy and reduce off-target side effects.

Sign in / Sign up

Export Citation Format

Share Document